111 Inc – (NASDAQ:YI) Given Average Rating of “Strong Buy” by Brokerages

Shares of 111 Inc – (NASDAQ:YI) have received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Analysts have set a 12 month consensus price target of $14.00 for the company, according to Zacks. Zacks has also given 111 an industry rank of 70 out of 256 based on the ratings given to related companies.

Shares of YI stock opened at $7.16 on Thursday. 111 has a 1-year low of $5.60 and a 1-year high of $16.83. The firm has a market cap of $599.35 million and a P/E ratio of -6.45.

111 (NASDAQ:YI) last announced its earnings results on Thursday, March 7th. The company reported ($0.22) earnings per share for the quarter. The company had revenue of $81.07 million during the quarter. As a group, analysts predict that 111 will post -1.32 earnings per share for the current year.

A hedge fund recently raised its stake in 111 stock. Chiron Investment Management LLC lifted its stake in 111 Inc – (NASDAQ:YI) by 4.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,407,509 shares of the company’s stock after buying an additional 61,626 shares during the quarter. 111 makes up 1.1% of Chiron Investment Management LLC’s holdings, making the stock its 28th largest position. Chiron Investment Management LLC owned about 1.73% of 111 worth $8,473,000 as of its most recent filing with the Securities & Exchange Commission. 3.93% of the stock is owned by hedge funds and other institutional investors.

111 Company Profile

111, Inc, through its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services, such as online consultation services and e-prescription services to consumers.

Recommended Story: How does a security become overbought?

Get a free copy of the Zacks research report on 111 (YI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for 111 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 111 and related companies with MarketBeat.com's FREE daily email newsletter.